scholarly journals Association between IgG4 Autoantibody and Complement Abnormalities in Systemic Lupus Erythematosus

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Qingjun Pan ◽  
Linjie Guo ◽  
Jing Wu ◽  
Jun Cai ◽  
Huanjin Liao ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Lupus Nephritis ◽  
Inflammatory Response ◽  
Lupus Erythematosus ◽  
Serum Levels ◽  
Clinical Parameters ◽  
Newly Diagnosed ◽  
Systemic Lupus ◽  
Novel Therapeutic

In order to investigate the association between IgG4 autoantibody and complement abnormalities in systemic lupus erythematosus (SLE), 72 newly diagnosed SLE patients, 67 rheumatoid arthritis (RA) patients, and 41 healthy normals were employed. Serum levels of antinuclear IgG4 and IgG4-specific IgM-rheumatoid factor (RF) were measured, and the correlations between serum levels of antinuclear IgG4 and several clinical parameters were analyzed. Also, the levels of IgG subclasses, C1q, and C3 deposition in lupus nephritis (LN) were detected. The results showed that serum levels of antinuclear IgG4 were higher in SLE patients relative to healthy normals (P<0.01). Serum levels of antinuclear IgG4 in SLE patients were positively correlated with serum levels of total IgG4, albumin, and C3 (r=0.61,P<0.05;r=0.40,P<0.05; andr=0.54,P<0.05, resp.) and negatively correlated with 24-hour urinary protein (r=0.49,P<0.05). Serum levels of IgG4-specific IgM-RF were higher in RA patients than in SLE patients (P<0.001). Also, the ratio of the deposition score for IgG4/(IgG1 + IgG2 + IgG3 + IgG4) was negatively correlated with the score for C1q and C3 deposition in LN (r=0.34,P<0.05;r=0.51,P<0.01, resp.). In summary, the IgG4 autoantibody may dampen the inflammatory response in SLE, thus maybe providing a novel therapeutic target for SLE.

scholarly journals Assessing the expression of immunosuppressive cytokines in the newly diagnosed systemic lupus Erythematosus patients: a focus on B cells

2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Mitra Abbasifard ◽  
Zahra Kamiab ◽  
Mohammad Hasani ◽  
Amir Rahnama ◽  
Pooya Saeed-Askari ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
B Cells ◽  
Immune Responses ◽  
Lupus Erythematosus ◽  
Healthy Subjects ◽  
Serum Levels ◽  
Newly Diagnosed ◽  
Systemic Lupus ◽  
Moderate Disease ◽  
Immunosuppressive Cytokines

Abstract Background The immunosuppressive effects of regulatory B-cells (Bregs) and their immunosuppressive cytokines on immune responses in autoimmune disorders, mainly systemic lupus erythematosus (SLE), have been recently established. Therefore, the purpose of this article has been the exploration of the expressions of cytokines produced by B cells in newly diagnosed SLE patients. Results The findings demonstrated that the gene expression of IL-10, TGF-β, IL-35, PD-L1, and FasL was significantly up-regulated in SLE patients compared to healthy subjects (P < 0.05). Additionally, the results revealed that serum levels of IL-10, TGF-β, IL-35, PD-L1 were remarkably increased in patients with SLE compared to healthy subjects (P < 0.0001). However, serum levels of IL-10 and TGF-β decreased significantly with increasing SLEDAI score in studied patients (P < 0.05). Conclusion It was concluded that the release of anti-inflammatory cytokines, particularly IL-10 and TGF-β, might inhibit immune responses and autoreactive immune cells in a compensatory manner in SLE patients with mild to moderate disease activity.

scholarly journals Comparative analysis of the systemic inflammatory response in rheumatic diseases

2012 ◽  
Vol 93 (1) ◽  
pp. 12-17
Author(s):  
D V Ivanov ◽  
L A Sokolova ◽  
E Yu Gusev ◽  
L N Kamkina ◽  
N O Plekhanova
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Ankylosing Spondylitis ◽  
Inflammatory Response ◽  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
C Reactive Protein ◽  
Systemic Lupus ◽  
Reactive Protein ◽  
Reactivity Coefficient

Aim. To compare the course of chronic systemic inflammation during various rheumatic diseases. Methods. Examined were three groups of patients: with ankylosing spondylitis - 25 people (20 males and 5 females), with rheumatoid arthritis - 26 people (11 males and 15 females) and with systemic lupus erythematosus - 49 people (3 males and 46 females). The control group included 50 practically healthy individuals (26 males and 24 females). Analyzed were the following parameters: the content of interleukin-6, -8, -10, C-reactive protein. The integral index of the reactivity coefficient was calculated. Results. The level of the studied cytokines was significantly higher in systemic lupus erythematosus, than in ankylosing spondylitis and rheumatoid arthritis, while the content of C-reactive protein was significantly higher in ankylosing spondylitis and rheumatoid arthritis. The values of the reactivity coefficient were also significantly higher in systemic lupus erythematosus. Conclusion. The presence of systemic inflammation was determined in most patients with systemic lupus erythematosus, while ankylosing spondylitis and rheumatoid arthritis were characterized only by mild manifestations of systemic inflammatory response.

Lack of Association of C-C Chemokine Receptor 5 Δ32 Deletion Status with Rheumatoid Arthritis, Systemic Lupus Erythematosus, Lupus Nephritis, and Disease Severity

2010 ◽  
Vol 37 (11) ◽  
pp. 2226-2231 ◽  
Author(s):  
HENK A. MARTENS ◽  
SACHA GROSS ◽  
GERRIT van der STEEGE ◽  
ELISABETH BROUWER ◽  
JO H.M. BERDEN ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Lupus Nephritis ◽  
Disease Severity ◽  
Chemokine Receptor ◽  
Lupus Erythematosus ◽  
Disease Susceptibility ◽  
Systemic Lupus ◽  
Genotype Frequencies ◽  
Chemokine Receptor 5

Objective.C-C chemokine receptor 5 (CCR5) plays an important role in inflammation. A 32 base-pair (Δ32) deletion in the CCR5 gene leads to a nonfunctional receptor. This deletion has been reported to have a protective effect on the development and progression of several autoimmune diseases. We investigated whether the Δ32 deletion is associated with disease susceptibility in a population of patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and lupus nephritis (LN); and whether it is associated with disease severity.MethodsDNA samples from 405 RA patients, 97 SLE patients, 113 LN patients, and 431 healthy controls were genotyped for the CCR5 Δ32 deletion. Differences in genotype frequencies were tested between patients and controls. Association of genotypes with disease severity was analyzed.ResultsGenotype frequencies of each group were in Hardy-Weinberg equilibrium. The genotype frequencies of patients did not differ significantly from controls (CCR5/Δ32, Δ32/Δ32: RA 18.3% and 1.2%, respectively; SLE 17.5% and 2.1%; LN 13.3% and 1.8%; controls 20.0% and 2.8%). However, there was a trend for lower Δ32 deletion allele frequency in LN patients compared to controls (p = 0.08). There was no significant association between the CCR5 status and disease severity in RA, SLE, or LN.Conclusion.Although an association with LN cannot be excluded, the CCR5 Δ32 deletion does not seem to be a disease susceptibility genotype for RA, SLE, or LN. No significant effect of the Δ32 deletion on disease severity was demonstrated.

Successful tocilizumab and tacrolimus treatment in a patient with rheumatoid arthritis complicated by systemic lupus erythematosus

Lupus ◽  
2012 ◽  
Vol 21 (9) ◽  
pp. 1003-1006 ◽  
Author(s):  
K Maeshima ◽  
K Ishii ◽  
M Torigoe ◽  
C Imada ◽  
M Iwakura ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Combination Therapy ◽  
Lupus Erythematosus ◽  
Renal Involvement ◽  
Oral Prednisolone ◽  
Serum Levels ◽  
High Dose ◽  
Systemic Lupus ◽  
High Level

We report a 37-year-old female of intractable rheumatoid arthritis (RA) complicated by systemic lupus erythematosus (SLE), who was successfully treated with a combination of tocilizumab (TCZ) and tacrolimus. She was diagnosed with RA when she was 21 years old, and was administered oral prednisolone, injectable gold and salazosulfapyridine, but deformity of her hands gradually developed. She developed high fever and thrombocytopenia when she was 35 years old. Renal involvement, pericarditis, positive antinuclear antibody and high level of anti-double-stranded DNA antibody were found and the patient was diagnosed with SLE. Polyarthritis and immunological abnormalities developed despite aggressive immunosuppressive therapy including high-dose corticosteroids and intravenously administered cyclophosphamide. Tacrolimus (TAC) therapy gave only partial improvement of joint symptoms. After the initiation of combination therapy with TCZ, not only was a complete remission of RA obtained, but also the serum levels of SLE markers dramatically decreased. Our report suggests the possibility that this combination therapy is effective in treating SLE as well as RA.

scholarly journals COVID-19 triggered systemic lupus erythematosus in a child: a case report

2021 ◽  
Vol 8 (7) ◽  
pp. 1304
Author(s):  
Krishna Prasad Maram ◽  
Venkata Rama Rao Paturi ◽  
Lalitha Sudha Alla ◽  
Murali Krishna Bhagavatula
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Case Report ◽  
Lupus Nephritis ◽  
Inflammatory Response ◽  
Organ Dysfunction ◽  
Lupus Erythematosus ◽  
Immune Disorders ◽  
Systemic Lupus ◽  
Pediatric Systemic Lupus Erythematosus ◽  
Second Wave

The COVID-19 pandemic has continued to wreak havoc globally during the second wave. Even though it tends to be asymptomatic or cause only a trivial illness in children, it is reported to be associated with a delayed hyper-inflammatory response syndrome resulting in multi-organ dysfunction in children. It is possible that through unknown mechanisms, it could also result in triggering of other auto-immune disorders. We report a case of pediatric systemic lupus erythematosus (SLE) with lupus nephritis suspected to be triggered by SARS-CoV-2 virus which is not reported in the literature so far.

scholarly journals Rapidly progressive lupus nephritis associated with golimumab in a patient with systemic lupus erythematosus and rheumatoid arthritis

Lupus ◽  
2016 ◽  
Vol 26 (4) ◽  
pp. 447-448 ◽  
Author(s):  
Y Saka ◽  
Y Taniguchi ◽  
Y Nagahara ◽  
R Yamashita ◽  
M Karasawa ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Lupus Nephritis ◽  
Lupus Erythematosus ◽  
Systemic Lupus
Sign in / Sign up

Export Citation Format

Share Document